Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2014; 20(40): 14733-14746
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Table 1 Major adjuvant chemotherapy trials in pancreatic cancer
| Final analysis | Survival (95%CI) | Disease-free survival (DFS)(95%CI) | |||||||||||||
| Year published | Author/group | Treatment arms (n) | T3 | N+ | R0 | Median survival (mo) | 1-yr survival | 2-yr survival | 3-yr survival | 5-yr survival | Median DFS (mo) | 1-yr DFS | 2-yr DFS | 3-yr DFS | 5-yr DFS |
| 1993 | Bakkevold | 5-FU/doxorubicin/mitomycinc (30) | NA | NA | 100% | 23 | - | 70% | 27% | 4% | - | - | - | - | - |
| Surgery alone (31) | 11 (P = 0.02) | 45% | 30% | 8% (P = 0.1) | |||||||||||
| 2001 | ESPAC-1 (all patients) | 5-FU/folinic fcid +/- CRT (238) | NA | 53% | 82% | 19.7 (16.4-22.4) | - | - | - | - | - | - | - | - | - |
| No chemotherapy +/- CRT (235) | 14 (11.9-16.5) (HR = 0.66, 0.52-0.83, P = 0.0005) | ||||||||||||||
| ESPAC-1 (2 × 2 design only) | 5-FU/folinic fcid +/- CRT (146) | NA | NA | NA | 17.4 (13.5-21.8) | - | - | - | - | - | - | - | - | - | |
| No chemotherapy +/- CRT (139) | 15.9 (13.5-19.2) (HR = 0.82, 0.6-1.11, P = 0.19) | ||||||||||||||
| 2002 | Takada | 5-FU/mitomycin C (89) | NA | 85% | 58% | NA | - | - | - | 11.5% | - | - | - | - | 8.6% |
| Surgery alone (84) | 18% (log rank NS) | 7.8% (log rank P = 0.84) | |||||||||||||
| 2004 | ESPAC-1 (2 × 2 final analysis) | 5-FU/folinic fcid (147) | NA | 54% | 82% | 20.1 (16.5-22.7) | - | 40% | - | 21% | - | - | - | - | - |
| No chemotherapy +/- CRT (142) | 15.5 (13-17.7) (HR = 0.71, 0.55-0.92, P = 0.009) | 30% | 8% | ||||||||||||
| 2006 | JSAP (Kosuge) | Cisplatin/5-FU (45) | NA | 27% | 100% | 12.5 | - | - | - | 26.4% | - | - | - | - | - |
| Surgery alone (44) | 15.8 | 14.9% (P = 0.94) | |||||||||||||
| 2007 | CONKO-001 (Oettle) | Gemcitabine (179) | 22.1 (18.4-25.8) | 72.5% | 47.5% | 34% | 22.5% | 13.4 (11.4-15.3) | 58% | 30.5% | 23.5% | 16.5% | |||
| Surgery alone (175) | 86 | 72% | 83% | 20.2 (17-23.4) (P = 0.06) | 72.5% | 42% | 20.5% | 20.5% | 6.9 (6.1-7.8) (P < 0.001) | 31% | 14.5% | 7.5% | 5.5% | ||
| 2008 | CONKO-001 Final (Neuhaus) | Gemcitabine (179) | 22.8 | - | - | 36.5 | 21 | 13.4 | - | - | 23.5 | 16.0 | |||
| Surgery alone (175) | 20.2 (P = 0.005) | 19.5% | 9% | 6.9 (P < 0.001) | 8.5% | 6.5% | |||||||||
| 2009 | JSAP-2 (Ueno) | Gemcitabine +/- RT (58) | 86% | 69% | 84% | 22.3 (16.1-30.7) | 77.6% | 48.3% | - | 23.9% | 11.4 (8-14.5) | 49% | 27.2% | - | - |
| Surgery alone +/- RT (60) | 18.4 (15.1-25.3) (HR = 0.77, 0.51-1.14, P = 0.19) | 75% | 40% | 10.6% | 5 (3.7-8.9) (HR = 0.6, 0.4-0.89, P = 0.01) | 26.7% | 16.7% | ||||||||
| 2009 | Collated data ESPAC-1, ESPAC-1 plus, ESPAC-3(v1) | 5-FU/folinic fcid (233) | NA | 55% | 75% | 23.2 (20.1-26.5) | 77% | 49% | - | 24% | - | - | - | - | - |
| Surgery alone (225) | 16.8 (14.3-19.2) (HR = 0.7, 0.55-0.88, P = 0.003) | 63% | 37% | 14% | |||||||||||
| 2010 | ESPAC-3(v2) | 5-FU/folinic fcid (551) | NA | 72% | 65% | 23 (21.1-25) | 78.5% (75%-82%) | 48.1% (43.8%-52.4%) | - | - | 14.1 (12.5-15.3) | 56.1% (51.8%-60.3%) | 30.7% (26.7%-34.6%) | - | - |
| Gemcitabine (537) | 23.6 (21.4-26.4) (HR = 0.94, 0.81-1.08, P = 0.39) | 80.1% (76.7%-83.6%) | 49.1% (44.8-53.4%) | 14.3 (13.5-15.6) | 61.3% (57.1%-65.5%) | 29.6% (25.6%-33.5%) | |||||||||
| 2013 | JASPAC-01 | S-1 (187) | 87% | 63% | 87% | 46.3 | - | 70% | - | - | 23.2 | - | 49% | - | - |
| Gemcitabine (191) | 25.5 (P < 0.0001) | 53% (HR = 0.56, 0.42-0.74, P < 0.0001) | 11.2 (log rank P < 0.0001) | 29% (HR = 0.56, 0.43-0.71, log rank P < 0.0001) | |||||||||||
- Citation: Jones OP, Melling JD, Ghaneh P. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2014; 20(40): 14733-14746
- URL: https://www.wjgnet.com/1007-9327/full/v20/i40/14733.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i40.14733